FDA Puts Full Hold on Clinical Testing of Cortexyme’s COR388

Home / Alzheimer's / FDA Puts Full Hold on Clinical Testing of Cortexyme’s COR388
FDA Puts Full Hold on Clinical Testing of Cortexyme’s COR388
February 08, 2022February 8, 2022
0

The U.S. Food and Drug Administration (FDA) has placed a full clinical hold on COR388 (atuzaginstat), an investigational oral therapy Cortexyme is developing for Alzheimer’s disease and now cancer. The decision means that Cortexyme will not be allowed to conduct in-person testing of COR388 until further notice. The company will provide further updates pending additional communication with the FDA, according to a press release. In the meantime, Cortexyme will be prioritizing the development of a similar…

You must be logged in to read/download the full post.

The post FDA Puts Full Hold on Clinical Testing of Cortexyme’s COR388 appeared first on BioNewsFeeds.